RVL Pharmaceuticals plc (RVLP) Tops Q2 EPS by 10c

RVL Pharmaceuticals plc (NASDAQ: RVLP) reported Q2 EPS of ($0.14), $0.10 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.72 million.

For earnings history and earnings-related data on RVL Pharmaceuticals plc (RVLP) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
• MidWestOne Financial Group, Inc. (MOFG) Misses Q1 EPS by 15c